The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer

Jonathan Ledermann, MD
Published Online: 4:23 PM, Fri September 8, 2017

Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.